Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAetna Homocysteine Testing Coverage Update | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0763

    Homocysteine Testing

    Customize your policy alerts

    Sign up for Aetna Policy 0763 alerts

    Get alerted when Policy 0763 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when measurement of plasma homocysteine is considered medically necessary or experimental/investigational for Aetna members; it applies to ordering and coverage decisions for homocysteine testing.

    Policy Summary
    PayerAetna
    PolicyHomocysteine Testing
    Policy CodePolicy 0763
    Change TypeNo material change
    Effective Date08/08/2008
    Last ReviewOct 26, 2023
    Next Review Date08/22/2024
    Key ActionDocument a covered clinical indication that meets one of the medically necessary criteria when ordering homocysteine testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    83090CPT code listed
    08/08/2008Policy effective
    10/26/2023Last review
    08/22/2024Next review
    listed indicationsCovered vs not-covered indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    38%pHcy decrease in trial

    Coverage Criteria

    inv-01: Medically Necessary

    Covered when ANY one of the following indications is documented:

    Medically necessary indications: Assessment of borderline vitamin B12 deficiency when the results will impact management.

    Document rationale and relevant B12/holotranscobalamin or methylmalonic acid results as applicable.

    Medically necessary indications: Assessment of central retinal vein occlusion when the member has a history of prior thrombosis, a family history of thrombosis, or is under age 56 years without strong arteriosclerotic risk factors.age <56 years

    Document absence of common local risk factors (eg, hypertension, glaucoma, diabetes) when ordering selective thrombophilia testing.

    Medically necessary indications: Assessment for homocystinuria caused by cystathionine beta synthase (CBS) deficiency (for newborn screening, plasma and/or urine homocysteine measurements are performed only when hyper-methioninemia has been confirmed).target pHcy <11 micromol/L for treated newborns

    Order plasma and/or urine Hcy and plasma amino acids for newborns or at‑risk siblings immediately after birth when hyper-methioninemia is confirmed.

    Medically necessary indications: Assessment of idiopathic venous thrombo-embolism, recurrent VTE, thrombosis at a young age (eg, <45 years), or thrombosis at an unusual site.

    Measurement may augment thrombophilia assessment and could influence anticoagulation duration when other thrombophilias are present; an elevated Hcy alone typically does not change management.

    inv-02: Experimental and Investigational / Not Medically Necessary

    Not covered — Aetna considers homocysteine testing experimental and investigational for all other indications, including but not limited to:

    Experimental/Investigational indications: Use of Hcy as a biomarker for erectile dysfunction, gastric cancer, pre-eclampsia, carotid artery stenosis with coronary artery disease, diabetic nephropathy or retinopathy, hematological complications of COVID-19, age-related macular degeneration, Alzheimer's disease, cognitive impairment/dementia, depression, or movement disorders.

    Evidence is observational or inconsistent; effectiveness not established.

    Experimental/Investigational indications: Assessment of acquired thrombophilia or arterial thrombosis in newborns; routine cardiovascular disease or stroke risk screening in asymptomatic individuals; management of MTHFR abnormalities.

    Randomized trials and guideline statements do not support routine screening or management based on Hcy for these indications.

    Experimental/Investigational indications: Assessment or monitoring in conditions such as autism, Down syndrome, Gaucher's disease, HELLP syndrome, lung transplant candidacy, Meniere's disease, migraine, multiple sclerosis (for routine clinical management), polycystic ovary syndrome, premature ovarian failure, primary carnitine deficiency, IVF planning, celiac disease, inflammatory bowel disease, pulmonary hypertension, and monitoring therapies (eg, methotrexate, s-adenosylmethionine, RTD-2).

    inv-03: Testing in thrombosis evaluation

    Covered when used as part of a targeted thrombosis evaluation in selected patients:

    Thrombosis evaluation: Measurement of plasma homocysteine may be considered when ordered as part of an evaluation for venous thromboembolism in patients with idiopathic VTE, recurrent VTE, thrombosis at a young age (eg, <45 years), or thrombosis at an unusual site.

    An elevated Hcy alone generally does not alter management but may augment risk assessment when other thrombophilias are present and could influence anticoagulation duration; document clinical context and prior tests.

    inv-04: Testing related to fracture/osteoporosis risk

    Covered in research settings or specific high‑risk clinical contexts:

    Fracture/osteoporosis contexts: Testing has been used in studies linking elevated total homocysteine (tHcy) to increased hip fracture risk and in trials assessing folate plus vitamin B12 therapy to reduce fractures in high‑risk post‑stroke hemiplegic patients.tHcy >= 15 micromol/L

    Evidence is mixed; benefit of vitamin therapy was shown in a selected elderly post‑stroke hemiplegic cohort but is not established for general fracture prevention.

    inv-05: Cardiovascular disease and stroke — routine screening

    Not indicated for routine screening of asymptomatic individuals for cardiovascular disease or stroke:

    Cardiovascular screening: Routine measurement of homocysteine to screen asymptomatic individuals for coronary heart disease or stroke prevention is not supported by randomized trial evidence and guideline statements.

    Multiple large RCTs and systematic reviews failed to demonstrate clinical benefit from homocysteine‑lowering interventions despite reductions in biochemical levels; USPSTF and editorial guidance do not recommend routine screening.

    inv-06: Use of percent change in tHcy to monitor folic acid therapy (research/selected populations)

    Use in research or select trial-derived contexts to monitor treatment effect:

    Percent-change monitoring: Percent decline in total homocysteine (tHcy) has been associated with reduced first‑stroke risk in a post‑hoc CSPPT analysis; a 20% decline in tHcy was associated with ~7% reduction in stroke risk in that cohort.20% decline

    This metric may serve as an indicator of treatment efficacy in research settings or selected hypertensive populations but is not an established routine clinical monitoring standard; findings require confirmation.

    inv-07: Retinal vein occlusion — selective testing

    Selective testing may be considered in atypical retinal vein occlusion presentations:

    Retinal vein occlusion - selective testing: In young patients or those with unexpected retinal vein occlusion and a personal or family history of thrombosis (or bilateral disease), clinicians may include homocysteine measurement as part of a full thrombophilia workup or within a clinical trial context.age <50-56 years or presence of thrombosis history

    Routine testing in all RVO patients is not recommended; document absence of common risk factors (eg, hypertension, glaucoma, diabetes) when ordering selective thrombophilia testing.

    inv-08: Cardiovascular disease risk prediction

    Observational data support Hcy as an adjunctive risk marker but not for routine screening:

    CVD risk reclassification: Elevated homocysteine (eg, >15 μmol/L) has been associated with increased cardiovascular and coronary heart disease risk in cohort analyses and, when added to Framingham Risk Score models, improved risk reclassification (net reclassification improvement reported).>15 μmol/L

    Evidence is observational; further trials are needed before recommending routine clinical use for risk reclassification.

    inv-09: Situations where Hcy testing may be appropriate

    Consider Hcy testing in the following targeted clinical situations when documentation supports the indication:

    RVO selected testing: Order homocysteine and broader thrombophilia testing in patients with retinal vein occlusion who are young (eg, <50 or <56 years), have bilateral CRVO, have a personal or family history of thrombosis, or when common local risk factors are absent.age <50-56 or presence of thrombosis history

    Testing should be targeted and documented; routine inclusion in pregnancy thrombophilia panels is discouraged.

    Pregnancy/thrombophilia guidance: Do not include homocysteine measurement as part of routine thrombophilia screening in pregnancy; selective testing for pregnancy‑related indications is not supported by guideline recommendations.N/A

    Refer to UpToDate and ACOG guidance cited in policy.

    Recurrent miscarriage evaluation: In women with a history of recurrent miscarriage, testing for homocysteine in conjunction with antiphospholipid antibodies and factor V Leiden may be justified based on the literature.

    This policy explicitly excludes the use of homocysteine testing for management of MTHFR abnormalities and lists numerous clinical conditions and screening uses as not covered. Examples include assessment of autism, cardiovascular disease or stroke risk, cognitive impairment/dementia, depression, Down syndrome, fracture risk, Gaucher's disease, HELLP syndrome, lung transplant candidates, Meniere's disease, migraine, movement disorders, multiple sclerosis, polycystic ovary syndrome, premature ovarian failure, primary carnitine deficiency, recurrent pregnancy loss, retinal artery/branch vein occlusion, in‑vitro fertilization planning, management of celiac disease or inflammatory bowel disease, pulmonary hypertension, and monitoring of methotrexate or other specific therapies.

    Routine measurement of homocysteine to screen asymptomatic men and women with no history of coronary heart disease (CHD) for the prevention of CHD events is not supported. The USPSTF found insufficient evidence to recommend screening, and systematic reviews and randomized trials of B‑vitamin supplementation that lowered homocysteine did not demonstrate reduced cardiovascular events, so routine population screening is not endorsed.

    The American College of Obstetricians and Gynecologists (ACOG, 2014) does not recommend screening with MTHFR mutation analyses or fasting homocysteine levels when evaluating inherited thrombophilias in pregnancy, citing lack of association between MTHFR C677T polymorphism and adverse pregnancy outcomes.

    There is insufficient evidence to support routine homocysteine testing for a wide range of conditions. The policy specifically lists acquired thrombophilia, autism, Down syndrome, Gaucher's disease, HELLP syndrome, Meniere's disease, methotrexate therapy monitoring, response to vitamin B‑12 therapy, movement disorders, primary carnitine deficiency, and pulmonary hypertension among indications lacking sufficient evidence for routine testing.

    Homocysteine measurement is not recommended as part of routine thrombophilia screening in pregnancy. UpToDate and ACOG guidance advise against including homocysteine testing or MTHFR polymorphism testing in standard pregnancy thrombophilia panels.

    In the provided sections there are no additional explicit coverage exclusions beyond those enumerated elsewhere in the policy; routine and investigational uses are addressed in the Experimental/Not Medically Necessary and Not Covered sections.

    Testing for cardiovascular disease or stroke risk and many other diagnostic or monitoring uses is not supported as routine care. The policy cites randomized trials and systematic reviews showing that lowering homocysteine with B‑vitamin therapy did not reduce cardiovascular events, and therefore routine Hcy testing for CVD/stroke risk assessment or to guide B‑vitamin therapy is not recommended.

    The use of homocysteine testing for routine cardiovascular risk assessment in asymptomatic individuals without specific clinical indications is not supported by the evidence and is considered not medically necessary. Major guideline reviews and randomized trial data do not support population‑level screening or routine use to prevent ischemic stroke or CHD events.

    Routine homocysteine testing for age‑related macular degeneration (ARMD) or retinal vein occlusion (RVO) is not supported. Systematic reviews and meta‑analyses report heterogeneity and possible publication bias, and the evidence is insufficient to recommend routine investigation or treatment based on homocysteine levels for these ocular conditions.

    Routine homocysteine testing for all patients with retinal vein occlusion is not recommended. The policy supports selective testing in young patients or those with atypical presentations and thrombosis history, but routine use as a standard component of thrombophilia screening in pregnancy or for all RVO cases is discouraged until a clear role and impact on treatment are established.

    The sections provided do not contain explicit language using the phrase 'not medically necessary' for every listed item; instead, the policy characterizes many indications as experimental and investigational or not covered based on insufficient evidence and cites relevant guideline conclusions.

    Covered Indications and Use Cases

    inv-67: Assessment of borderline vitamin B12 deficiency when results will impact management

    Covered when results will affect clinical management:

    Borderline B12 assessment: Measurement of plasma homocysteine may be used to assess borderline vitamin B12 deficiency when the test result will impact patient management (eg, when B12 markers are equivocal).

    Document how the result will change management and consider corroborating tests (eg, methylmalonic acid, holo‑transcobalamin).

    inv-68: Assessment of central retinal vein occlusion with prior thrombosis, family history of thrombosis, or age <56 without strong arteriosclerotic risk factors

    Covered selectively for CRVO when thrombotic predisposition is suspected:

    CRVO with thrombosis history: Assessment of central retinal vein occlusion with prior thrombosis, family history of thrombosis, or age <56 years without strong arteriosclerotic risk factors may include homocysteine testing as part of a thrombophilia evaluation.age <56 years

    Coding and Definitions

    Covered CPT Codes (if selection criteria are met)CPTCovered
    83090Homocysteine
    ICD-10 codes covered when medically necessaryICD-10
    D51.0 - D51.9Vitamin B12 deficiency anemia
    D81.818Other biotin-dependent carboxylase deficiency
    D81.819Biotin-dependent carboxylase deficiency, unspecified
    E53.8Deficiency of other specified B group vitamins
    E72.10 - E72.11 E72.19Disturbances of sulphur-bearing amino-acid metabolism
    H34.8110 - H34.8192Central retinal vein occlusion
    I26.01 - I26.99Pulmonary embolism
    I81Portal vein thrombosis
    I82.0 - I82.91Other venous embolism and thrombosis
    ICD-10 codes noted as not covered for certain indications listed in the CPB (not all-inclusive)ICD-10Not Covered
    C16.0 - C16.9Malignant neoplasm of stomach
    D68.51 - D68.69Primary or other thrombophilia
    E10.10 - E13.9Diabetes mellitus
    G30.0 - G30.9Alzheimer's disease
    G35Multiple sclerosis
    G43.001 - G43.919Migraine
    H81.01 - H81.09Meniere's disease
    I27.0, I27.20 - I27.29Pulmonary hypertension
    K90.0Celiac disease
    N96Habitual aborter
    Plasma homocysteine normal/desirable thresholds
    Normal plasma homocysteineApproximately 12 micromol/L
    Desirable plasma homocysteineLess than 10 micromol/L
    Fasting measurement contextHcy measurements are usually performed after fasting
    Homocysteine elevation categories
    Moderate elevation15–30 micromol/L
    Intermediate elevation31–100 micromol/L
    Severe elevation

    Provider Actions and Authorization

    Prior Authorization

    Prior authorization for CPT 83090

    Prior authorization may be required for CPT 83090. Coverage for CPT 83090 (homocysteine) is limited to tests meeting the medically necessary selection criteria — verify the indication matches policy criteria prior to authorization.

    • Affected code: CPT 83090
    Documentation Required

    Required clinical indication / Indications not listed may be denied

    Document the clinical indication at the time of order. Testing for indications not listed as medically necessary may be denied; if ordering for an unlisted indication, include supporting clinical rationale in the record.

    • Required clinical indication must meet a medically necessary indication
    • If ordering for non-covered indications, document rationale

    Ordering Requirements

    Billing Rule

    Ordering must document a covered clinical indication; no clinician restriction stated

    Order homocysteine testing only when the requisition documents one of the covered clinical indications; no restriction on ordering clinician type is specified in the cited text.

    • Ensure the order includes the covered indication (e.g., selected thrombophilia evaluation, newborn confirmation of homocystinuria after hyper-methioninemia).
    • No specific specialist-only ordering requirement is stated.
    Note

    Order Hcy as part of targeted diagnostic evaluation or to monitor vitamin therapy

    Order homocysteine testing when it is part of a targeted diagnostic evaluation (e.g., thrombosis workup) or when monitoring response to vitamin therapy in specific patients; document the clinical rationale and prior treatments/results.

    Frequency Limits

    Frequency limits
    Explicit frequency limitsNo explicit frequency limits specified in this portion of the document
    Policy review dates relevant to frequency guidanceLast review 10/26/2023; Next review 08/22/2024
    Clinical contextRecommendations emphasize selective, clinically indicated testing rather than routine repeated measures
    Percent-change monitoring in trials
    Percent-change monitoring in trialsTrials measured percent change in tHcy from baseline to study end (example: CSPPT measured baseline and exit tHcy)
    Clinical frequencyClinical monitoring frequency not established; trial-based measurements at baseline and end of follow-up

    Not Covered / Limitations

    Testing for many indications listed as experimental and investigational is designated as not covered. This includes routine cardiovascular disease or stroke risk assessment, management of MTHFR abnormalities, and numerous neurologic, reproductive, ophthalmologic, and other conditions noted in the policy's exclusions and not‑covered lists.

    Population‑wide or routine cardiovascular homocysteine screening in asymptomatic individuals without specific risk factors or clinical indications is considered not covered, reflecting USPSTF and systematic review findings that do not support benefit from such screening.

    Routine investigation and treatment of elevated total homocysteine (tHcy) in retinal vein occlusion cannot be recommended due to study heterogeneity and possible publication bias; therefore routine testing and treatment in this context are not supported.

    Routine homocysteine testing for a wide range of conditions listed as having insufficient evidence is not covered. The policy identifies numerous conditions (see exclusions) where routine Hcy measurement is not supported by current evidence.

    Routine homocysteine testing as part of pregnancy thrombophilia screening is not covered; UpToDate guidance recommends avoiding homocysteine measurement and MTHFR testing in routine pregnancy thrombophilia evaluations.

    Within the provided excerpts there are no additional explicit statements listing individual tests or indications as categorically not covered beyond the Experimental/Not Medically Necessary and Not Covered sections already summarized.

    Background and Definitions

    Homocysteine (Hcy) is a sulfur‑containing amino acid formed from methionine and metabolized via vitamin‑dependent pathways: B12/folate‑dependent remethylation or B6‑dependent transsulfuration. Plasma tHcy is measured fasting and reported in micromoles per liter.

    Hyper-homocysteinemia and related definitions
    Hyper-homocysteinemia categoriesModerate: 15–30 μmol/L; Intermediate: 31–100 μmol/L; Severe: >100 μmol/L
    MTHFR C677T TT genotypeCommon variant associated with mildly elevated pHcy, especially with low folate
    pHcy / tHcy definitionsPlasma (pHcy) or total homocysteine (tHcy) measured in μmol/L
    MTHFR C677T thermo-labile variant (TT genotype)
    MTHFR C677T TT genotype frequencyPopulation frequency estimated between ~5% to 14%

    Key Definitions

    Hyper-homocysteinemia categories — recap
    Hyper-homocysteinemia categories reminderModerate: 15–30 μmol/L; Intermediate: 31–100 μmol/L; Severe: >100 μmol/L
    Measurement contextFasting plasma Hcy commonly used to classify severity
    Clinical causesGenetic defects, vitamin deficiencies, chronic diseases, and certain medications
    MTHFR C677T variant — genotype context
    MTHFR C677T variant — population contextTT genotype frequency ~5–14% in general populations
    Effect on HcyAssociated with mildly elevated plasma homocysteine, more so with low folate
    Screening caveat

    Background and Evidence Summary

    In biochemical terms, homocysteine levels are influenced by B‑vitamin cofactors (folate, B12, B6) and genetic enzyme defects. Typical reference considerations note a normal plasma Hcy around ~12 micromol/L with a desirable level <10 micromol/L, and elevations categorized as moderate (15–30 μmol/L), intermediate (31–100 μmol/L), or severe (>100 μmol/L).

    The document lists numerous references associating homocysteine measurement with a wide range of conditions and research contexts. These citations support the policy's discussion of investigational uses and include studies and reviews on coronary heart disease/stroke risk, multiple sclerosis, polycystic ovary syndrome, osteoporosis/fracture risk, recurrent pregnancy loss, homocystinuria, IVF planning, retinal artery/vein occlusion, diabetic microvascular disease, pre‑eclampsia, COVID‑19 hematologic complications, and many other conditions.

    Revision History

    2023-10-26policy_reviewLatest

    Policy reviewed (Last Review date recorded).

    2008-08-08policy_effective

    Policy became effective on this date.

    Policy dates and review schedule
    Policy effective dateEffective: 08/08/2008
    Policy Summary
    PayerAetna
    PolicyHomocysteine Testing
    Policy CodePolicy 0763
    Change TypeNo material change
    Effective Date08/08/2008
    Last ReviewOct 26, 2023
    Next Review Date08/22/2024
    Key ActionDocument a covered clinical indication that meets one of the medically necessary criteria when ordering homocysteine testing.
    SourceLink
    On This Page
    Coverage CriteriaCovered Indications and Use CasesCoding and DefinitionsProvider Actions and AuthorizationOrdering RequirementsFrequency LimitsNot Covered / LimitationsBackground and DefinitionsKey DefinitionsBackground and Evidence SummaryRevision History

    List is not exhaustive; these uses are considered investigational per policy.

    Document prior obstetric history and rationale for ordering.

    Document atypical presentation, absence of common local risk factors, and rationale for thrombophilia testing.

    inv-69: Assessment of homocystinuria due to cystathionine beta synthase deficiency (newborn screening only when hyper-methioninemia confirmed)

    Covered for diagnostic confirmation in newborns/at‑risk siblings when screening abnormality present:

    Homocystinuria (CBS) assessment: Assessment of homocystinuria due to cystathionine beta synthase deficiency is covered; for newborn screening, plasma and/or urine homocysteine measurements are performed only when hyper‑methioninemia has been confirmed.target pHcy <11 micromol/L for treated newborns

    Measure plasma amino acids and Hcy in at‑risk siblings immediately after birth to enable early diagnosis and treatment.

    inv-70: Assessment of idiopathic venous thrombo-embolism, recurrent VTE, thrombosis at age <45, or thrombosis at an unusual site

    Covered when part of evaluation for concerning VTE presentations:

    Idiopathic/recurrent VTE: Assessment of idiopathic venous thrombo‑embolism, recurrent VTE, thrombosis at age <45 years, or thrombosis at an unusual site may include homocysteine testing as part of a thrombophilia workup.age <45 years

    Document clinical context; elevated Hcy alone is a relatively weak thrombosis risk factor but may augment assessment when combined with other thrombophilias.

    inv-71: Investigation of selected patients with venous thromboembolism (idiopathic, recurrent, young age, unusual site) — Measurement may augment assessment when other thrombophilias are present and could influence duration of anticoagulation.

    Measurement may augment thrombophilia evaluation when results could influence management:

    Selected VTE investigation: Measurement of homocysteine may be considered in selected patients with venous thromboembolism (idiopathic, recurrent, young age, unusual site) as part of a comprehensive thrombophilia evaluation; when other thrombophilias are present, results could influence duration of anticoagulation.

    Document all relevant thrombophilia testing and clinical decision implications.

    inv-72: Assessment in high-risk fracture populations or research protocols evaluating homocysteine–fracture relationships

    Covered in selected high‑risk fracture research or clinical protocols:

    Fracture research/high‑risk: Assessment in high‑risk fracture populations or within research protocols evaluating homocysteine–fracture relationships may be appropriate; select trials have shown fracture reduction with folate plus vitamin B12 in specific post‑stroke hemiplegic elderly cohorts.tHcy >= 15 micromol/L associated with higher risk

    Use in research or narrowly defined clinical contexts; not established for routine fracture risk screening.

    inv-73: Investigational or selected use in neurological disorders (e.g., MS) to explore associations with pHcy

    Investigational clinical use to explore associations where implications for management are uncertain:

    Neurological disorders (investigational): Investigational or selected use in neurological disorders (eg, multiple sclerosis) may be undertaken to explore associations with plasma homocysteine, but clinical relevance and management implications remain uncertain.

    Consider only in research settings or when findings would meaningfully inform care.

    inv-74: Newborn/at-risk sibling testing for homocystinuria when hypermethioninemia is confirmed

    Covered for newborns and at‑risk siblings when screening indicates metabolic disorder:

    Newborn/at‑risk sibling testing: Newborn or at‑risk sibling testing for homocystinuria (CBS deficiency) is covered when hyper‑methioninemia has been confirmed on newborn screening; perform plasma and/or urine Hcy and amino acid measurements to confirm diagnosis and enable early treatment.target pHcy <11 micromol/L

    Document newborn screening results and prompt confirmatory testing.

    inv-75: Evaluation of women with a history of recurrent miscarriage — testing Hcy, antiphospholipid antibodies and factor V Leiden is justified

    Covered as part of targeted recurrent miscarriage workup when clinically justified:

    Recurrent miscarriage evaluation: Evaluation of women with a history of recurrent miscarriage may include homocysteine testing together with antiphospholipid antibody testing and factor V Leiden assessment.

    Document obstetric history and rationale; follow related policy CPB 0348 as applicable.

    inv-76: Investigation of retinal artery/ocular ischemic syndromes when hypercoagulable state suspected

    Covered when systemic hypercoagulable state is suspected in ocular ischemic syndromes:

    Retinal artery/ocular ischemic syndromes: Investigation of retinal artery occlusion or ocular ischemic syndromes may include homocysteine measurement when a systemic hypercoagulable state is suspected as part of a broader workup.

    Consider concurrent testing (eg, CRP, lipid profile, creatinine) and document the clinical rationale.

    inv-77: Selected thrombophilia evaluation in young patients or those with unexpected retinal vein occlusion and personal/family thrombosis history

    Covered selectively in atypical young retinal vein occlusion presentations:

    Selected thrombophilia evaluation in young patients or those with unexpected retinal vein occlusion and a personal or family history of thrombosis may include homocysteine measurement as part of a full thrombophilia panel.age <50-56 or presence of thrombosis history

    Panel testing may include factor V Leiden, prothrombin G20210A, antiphospholipid antibodies, protein C/S, and antithrombin III; document atypical presentation.

    inv-78: Adjunct to cardiovascular risk assessment in research or select clinical contexts

    Investigational adjunct for cardiovascular risk assessment in research or select contexts only:

    Adjunct to CVD risk assessment: Homocysteine measurement may be used as an adjunctive marker for cardiovascular risk assessment in research or select clinical contexts where reclassification is being evaluated.>15 μmol/L

    Observational data show improved reclassification metrics, but routine clinical use is not established.

    inv-79: Evaluation for hypercoagulable state in young patients with central retinal vein occlusion, especially with bilateral disease or personal/family history of thrombosis.

    Consider homocysteine as part of a selective thrombophilia panel in young CRVO patients:

    CRVO hypercoagulable evaluation: Evaluation for a hypercoagulable state in young patients with central retinal vein occlusion — especially bilateral disease or with a personal/family history of thrombosis — may include homocysteine measurement as part of panel testing.

    Document patient age, bilateral involvement, prior thrombosis, and family history; include other thrombophilia tests as indicated.

    inv-80: Research or investigational use as a biomarker for diabetic nephropathy/retinopathy and pre-eclampsia risk where associations have been reported but evidence certainty is low.

    Investigational biomarker uses supported only in research settings due to low certainty:

    Diabetic complications & pre‑eclampsia (research): Research or investigational use of homocysteine as a biomarker for diabetic nephropathy/retinopathy and for pre‑eclampsia risk has been reported but evidence certainty is low.

    Not established for routine clinical screening; consider only in research protocols.

    inv-81: Exploratory biomarker for COVID-19 severity in patients with diabetes/obesity based on small observational data.

    Exploratory applications in preliminary observational data only:

    COVID‑19 biomarker (exploratory): Exploratory measurement of homocysteine as a biomarker of COVID‑19 severity in patients with diabetes and obesity has been described in small observational studies but is not standard of care.

    Consider only in research contexts; clinical utility unproven.

    inv-82: Investigational or diagnostic measurement of homocysteine in association with a wide range of conditions — lists references for each condition studied

    Investigational uses across a broad range of conditions — evidence insufficient to support routine clinical use:

    Wide-ranging investigational uses: Measurement of homocysteine for diagnostic or investigational purposes has been studied in numerous conditions (eg, CHD/stroke risk, multiple sclerosis, PCOS, osteoporosis/fracture risk, recurrent pregnancy loss, homocystinuria diagnosis, IVF planning, retinal artery/vein occlusion, and others) but is considered investigational for indications beyond those specifically listed as medically necessary.

    References cited in policy document list the studies; clinical utility is uncertain for most indications.

    >100 micromol/L
    High homocysteine
    High homocysteine threshold>= 15 micromol/L
    Study contextUsed in cohort analyses associating tHcy with fracture and CVD risk
    UnitsMicromoles per liter (μmol/L)
    Treatment effect on pHcy (hemiplegic stroke patients)
    Treatment effect (2-year hemiplegic stroke trial)pHcy decreased by 38% in folate+B12 treatment group vs increased by 31% in placebo
    PopulationElderly hemiplegic stroke patients (≥65 years)
    Outcome relevanceAssociated with reduced hip fracture incidence in the trial
    Target plasma Hcy for newborn-treated homocystinuria
    Target plasma Hcy for treated newborns with homocystinuriaMaintain pHcy below 11 micromol/L
    When measuredPerformed when hyper-methioninemia is confirmed on newborn screening
    SpecimenPlasma and/or urine Hcy
    Study thresholds cited
    High tHcy definition (study-cited)>= 15 micromol/L
    Study-specific hyper-homocysteinemia example95th percentile defined as ~15.8 micromol/L (Weger et al)
    Use in publicationsThresholds applied variably across cohort and case-control studies
    Homocysteine risk threshold
    Risk threshold referenced for CVD/CHD prediction> 15 μmol/L
    Evidence basisObserved associations with increased CVD/CHD events and improved risk reclassification in cohort analyses
    UnitsMicromoles per liter (μmol/L)
    Documentation Required

    Document vitamin evaluation or trials when testing to guide therapy

    When ordering Hcy testing to evaluate possible vitamin deficiency or to guide vitamin therapy, document prior assessment or trials of appropriate vitamin supplementation and monitored Hcy response when applicable (e.g., assessment of borderline vitamin B12 deficiency where results will impact management).

    • Document prior vitamin evaluation or therapeutic trial when relevant
    • Record how test results will change management
    Documentation Required

    ACOG / specialty guidance on MTHFR and homocysteine testing in pregnancy

    Follow ACOG guidance and specialty guidance: do not routinely screen for MTHFR polymorphisms or fasting homocysteine levels in pregnancy as part of inherited thrombophilia evaluation; MTHFR/homocysteine screening is not recommended.

    • Do not order MTHFR mutation analyses or fasting homocysteine as routine screening in pregnancy
    Documentation Required

    Retinal vein occlusion testing limitation and documentation

    Retinal vein occlusion: routine testing for homocysteine and other thrombophilia markers is not recommended for all patients. Consider selective testing in young patients (<56 years), bilateral/unexpected CRVO, or when personal or family history suggests a hypercoagulable state and after excluding common risk factors (e.g., hypertension, glaucoma, diabetes).

    • Document absence of common CRVO risk factors (hypertension, glaucoma, diabetes) when ordering Hcy testing for retinal vein occlusion
    • Selective testing supported for young patients, bilateral CRVO, or personal/family thrombosis history
    Denial Risk

    Limit routine cardiovascular screening and document indication

    Clinical guidance and evidence recommend against routine measurement of homocysteine for cardiovascular or arterial disease risk screening in asymptomatic individuals; routine screening may be denied. Document clinical indication if testing is ordered for cardiovascular concerns.

    • Routine cardiovascular or stroke risk screening with Hcy is not supported and may be denied
    • If ordered for cardiovascular reasons, document specific clinical justification
    Documentation Required

    UpToDate guidance on when to perform Hcy testing

    UpToDate guidance: do not perform homocysteine testing as part of routine thrombophilia screening in pregnancy; perform hypercoagulable workup (including homocysteine) only in patients with personal or family history suggesting hypercoagulable state or young patients without arteriosclerotic risk factors.

    • Avoid Hcy testing as routine in pregnancy thrombophilia screening
    • Consider Hcy testing in thrombophilia workup when personal/family history or young patients without arteriosclerotic risk factors
    Step Therapy

    No step therapy specified; consider verification of nutritional deficiency

    There are no explicit step therapy requirements specified for homocysteine testing in this policy. Consider verification of nutritional deficiencies (e.g., B12/folate) or alternative evaluations prior to testing when clinically appropriate.

    • No step therapy specified in policy
    • Consider verifying B12/folate deficiency or alternative tests before ordering Hcy
    Note

    Actions when a hereditary thrombophilia is identified

    If a hereditary thrombophilia is identified, refer to hematology and consider anticoagulation and family screening as clinically appropriate to reduce the risk of future thrombotic episodes.

    • Refer to hematology for identified hereditary defects
    • Consider anticoagulation and family member screening
    Note

    Policy history and review dates

    Policy history and review dates are provided in the policy header; check the policy record for last review and next review dates when validating coverage rules.

    • Effective date: 08/08/2008
    • Last review: 10/26/2023
    • Next review: 08/22/2024
    • Use Hcy testing to augment evaluation in idiopathic, recurrent, young-age, or unusual-site VTE when it may influence management.
    • When monitoring vitamin therapy, record supplementation history and measured changes in Hcy.
    Note

    Order Hcy testing for newborns/at-risk siblings after confirmed hypermethioninemia

    For homocystinuria evaluation, order Hcy (plasma and/or urine) when newborn screening indicates hypermethioninemia and for at-risk siblings immediately after birth; document amino acid and Hcy results to support diagnosis and early treatment.

    • Aim to maintain pHcy below 11 micromol/L in treated newborns.
    • Measure plasma amino acids and Hcy promptly in at-risk siblings to enable early intervention.
    Note

    Order Hcy (with APS and FVL) in evaluation of recurrent miscarriage — document history

    Testing for homocysteine, antiphospholipid antibodies, and factor V Leiden is justified in women with a history of recurrent miscarriage based on the literature cited; document the clinical history to support ordering.

    • Provide details of recurrent pregnancy losses and prior evaluations when ordering these tests.
    • ACOG guidance on inherited thrombophilias should be considered when testing in pregnancy.
    Note

    Order Hcy for selective thrombophilia workup in young/atypical CRVO patients

    Order homocysteine testing for selective thrombophilia workup in young or atypical retinal vein occlusion patients (e.g., age <50–56, bilateral disease, prior thrombosis, family history); document the atypical presentation and absence of common risk factors.

    • Include documentation of prior negative evaluations for hypertension, glaucoma, diabetes, and other local risk factors.
    • Specify age and family/personal thrombosis history to support targeted testing.
    Note

    Targeted ordering for young CRVO patients — document indications and prior negative evaluations

    Ordering should be targeted by clinicians evaluating young CRVO patients or those with suggestive personal/family history; include documentation of the indication and prior negative evaluation of common risk factors.

    • Testing is recommended only when common CRVO risk factors are absent and clinical features suggest hypercoagulability.
    • Document bilateral disease, age, and thrombosis history as applicable.
    Note

    No ordering provider restrictions stated

    No ordering clinician restrictions (such as specialist-only ordering) are specified in the provided policy text.

    Example associationIn CSPPT, a 20% decline in tHcy associated with ~7% reduction in stroke risk
    Plasma/urine Hcy for diagnosis and monitoring in homocystinuria
    Use for diagnosis/monitoring of homocystinuriaPlasma and/or urine Hcy used to confirm diagnosis and to monitor treatment in homocystinuria as clinically indicated
    Trigger for testingPerformed when newborn screening shows hyper-methioninemia; at-risk siblings tested immediately after birth
    Treatment goalMaintain pHcy below 11 micromol/L in treated newborns
    tHcy measurement sampling in cohorts
    Baseline tHcy sampling in cohortsMany cohort studies used a single baseline tHcy sample for risk assessment
    ImplicationSingle-sample baseline measurements limit inference about longitudinal change without repeat testing
    Units and reportingReported in micromoles per liter (μmol/L)
    Frequency guidance and selective one-time assessment
    Frequency guidance summaryNo explicit frequency limits provided; guidance emphasizes selective, often one-time diagnostic assessment when indicated
    Examples of selective approachesThrombophilia workup in young CRVO patients or newborn confirmation of homocystinuria
    Research monitoringTrials measure baseline and end-of-study tHcy; clinical translation of monitoring schedules not established
    Clinical relevanceHomozygosity for TT genotype is a relatively common cause of mildly elevated pHcy
    Interaction with folateEffect more pronounced when serum folate is low
    pHcy / tHcy — definitions and measurement context
    pHcy / tHcy measurementPlasma or total homocysteine concentration measured in blood, reported in μmol/L
    Fasting requirementMeasurements are usually performed after fasting
    Clinical usesBiomarker studied for vascular, neurologic, and metabolic conditions
    High tHcy — study thresholds and clinical implication
    High tHcy definition used in studies>=15 micromol/L (associated with increased risk in some cohorts)
    Example associationsLinked to higher hip fracture risk and CVD events in observational analyses
    Reporting unitsMicromoles per liter (μmol/L)
    Homocystinuria (CBS deficiency)
    Homocystinuria (CBS deficiency)Inherited disorder causing markedly elevated pHcy, tHcy and methionine; associated with thrombo-embolism and other features
    PrevalenceEstimated at approximately 1 in 200,000 to 335,000
    Newborn testing approachMeasure plasma/urine Hcy and amino acids when hyper-methioninemia confirmed to enable early treatment
    Study-specific hyper-homocysteinemia definition
    Study-specific hyper-homocysteinemia threshold95th percentile example = 15.8 micromol/L (Weger et al)
    ContextUsed to classify patients as hyper-homocysteinemic in retinal artery occlusion case-control study
    ImplicationDemonstrated higher odds of RAO in patients exceeding this threshold
    tHcy — abbreviation and measurement units
    tHcy abbreviation and unitstHcy = plasma total homocysteine, reported in μmol/L
    Use in researchUsed across cohort and case-control studies assessing associations with depression, RVO, and other conditions
    Analytic methodsFasting plasma tHcy commonly measured by HPLC or similar assays in cited studies
    CRVO — definition and testing context
    CRVO definition (clinical context)Central retinal vein occlusion: retinal venous thrombosis prompting evaluation for hypercoagulable states in younger/atypical patients
    Testing indicationConsider homocysteine as part of a thrombophilia workup in young patients, bilateral disease, or with thrombosis history
    Routine testing stanceNot recommended for routine testing until role and treatment impact are established
    Pregnancy thrombophilia screening — guidance
    Pregnancy thrombophilia screening guidanceDo not include homocysteine testing as part of routine thrombophilia screening in pregnancy
    RationaleUpToDate and ACOG guidance advise against routine Hcy and MTHFR testing in pregnancy
    Clinical practicePregnant patients routinely prescribed folic acid; isolated mildly elevated Hcy less predictive of VTE
    Cystathionine beta-synthase deficiency — diagnostic and management notes
    Cystathionine beta-synthase deficiency (CBS)Cause of homocystinuria characterized by very high Hcy and methionine; treatable when identified early
    Diagnostic testingMeasure plasma/urine Hcy and amino acids when newborn screening suggests hyper-methioninemia
    Management implicationEarly treatment aims to control pHcy (target <11 μmol/L) and reduce thrombotic complications
    Role of MTHFR screening in pregnancy is unclear and not routinely recommended
    pHcy / tHcy — measurement definition
    pHcy / tHcy measurementPlasma (pHcy) or total homocysteine (tHcy) measured in blood and reported in μmol/L
    Fasting requirementMeasurements are usually fasting specimens
    Clinical utilityUsed as biomarker in studies of vascular and other diseases; routine screening not established
    High tHcy — study and clinical implication
    High tHcy clinical implication>=15 μmol/L associated with increased risk in cohort studies and used as a study threshold
    Epidemiologic useApplied in fracture and CVD risk analyses
    Heterogeneity noteThresholds and associations vary across studies
    Homocystinuria — CBS deficiency
    Homocystinuria (CBS deficiency) summaryInherited disorder with markedly elevated Hcy; newborn screening and early treatment advised
    Testing triggersMeasure when hyper-methioninemia is confirmed on newborn screen; test at-risk siblings at birth
    Treatment goalMaintain plasma Hcy below 11 μmol/L in treated infants
    Study-specific hyper-homocysteinemia (example)
    Study-defined hyper-homocysteinemia example95th percentile = 15.8 μmol/L (Weger et al) used to classify RAO cases
    ApplicationExample of study-specific thresholding rather than a universal cutoff
    UnitsMicromoles per liter (μmol/L)
    tHcy — abbreviation and units
    tHcy abbreviationtHcy = plasma total homocysteine (μmol/L)
    Use in studiesCommon outcome/biomarker in cohort, case-control, and meta-analytic research
    Reporting unitsMicromoles per liter (μmol/L)
    CRVO — testing context and triggers
    CRVO clinical noteCentral retinal vein occlusion may prompt selective hypercoagulability testing including homocysteine in younger/atypical cases
    Testing triggersAge <56 (or <50), bilateral disease, prior thrombosis, or family history support selective testing
    Routine testing stanceNot recommended for all CRVO patients pending clearer causal/treatment evidence
    Pregnancy thrombophilia screening — testing recommendation
    Pregnancy thrombophilia screening recommendationGuidance advises against routine inclusion of homocysteine testing in pregnancy thrombophilia panels
    Source guidanceUpToDate and ACOG statements cited in policy
    Clinical rationaleRoutine Hcy testing in pregnancy lacks evidence of benefit and pregnant patients receive folic acid supplementation
    Last review date
    Last review: 10/26/2023
    Next scheduled reviewNext review: 08/22/2024